Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA PHARMACEUTICALS LIMITED
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Robert Hooper
Date of last notice	23/06/2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A	
Date of change	25/10/2016	
No. of securities held prior to change	34,815,792	
	Ordinary Shares	6,084,943
	Shares allocated pursuant to the employee share plan	33,612
	Shares allocated pursuant to the loan funded long term incentive plan	28,459,560
	Short term incentive plan	20,4,9,500
	performance rights	237,677
Class	Ordinary	

⁺ See chapter 19 for defined terms.

Number acquired	N/A	
Number disposed	272,608	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$382,151.76	
No. of securities held after change	34,543,184	
	Ordinary Shares	5,812,335
	Shares allocated pursuant to the employee share plan	33,612
	Shares allocated pursuant to the loan funded long term incentive plan	28,459,560
	Short term incentive plan performance rights	237,677
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	272,608 ordinary shares sold	on market

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to	
change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	

⁺ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Appendix 3Y Change of Director's Interest Notice

Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts	No
detailed above traded during a +closed period	
where prior written clearance was required?	
If so, was prior written clearance provided to	
allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.